Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cervetti G et al. – The present results indicate that this schedule is a valid therapeutic approach in SMZL. Addition of rituximab significantly improved quality of response and consequently the outcome of the disease.

Related Articles

Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT
Annals of Oncology, 10/29/09    Relevance Score: 95%

Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases
American Journal of Hematology, 11/09/09    Relevance Score: 94%

Primary cutaneous marginal zone lymphoma
Critical Reviews in Oncology/Hematology, 10/15/09    Relevance Score: 94%

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
Journal of Clinical Oncology, 10/08/09    Relevance Score: 94%

Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier
International Journal of Hematology, 10/13/09    Relevance Score: 93%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address